Toward a genome-based treatment landscape for renal cell carcinoma
• Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might infl...
Ausführliche Beschreibung
Autor*in: |
Massari, Francesco [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2019 |
---|
Schlagwörter: |
---|
Umfang: |
12 |
---|
Übergeordnetes Werk: |
Enthalten in: miR-214 in stroma cells and tumor progression - Dettori, D. ELSEVIER, 2016, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:142 ; year:2019 ; pages:141-152 ; extent:12 |
Links: |
---|
DOI / URN: |
10.1016/j.critrevonc.2019.07.020 |
---|
Katalog-ID: |
ELV047908513 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV047908513 | ||
003 | DE-627 | ||
005 | 20230624141859.0 | ||
007 | cr uuu---uuuuu | ||
008 | 191023s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.critrevonc.2019.07.020 |2 doi | |
028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000992.pica |
035 | |a (DE-627)ELV047908513 | ||
035 | |a (ELSEVIER)S1040-8428(19)30164-7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.52 |2 bkl | ||
100 | 1 | |a Massari, Francesco |e verfasserin |4 aut | |
245 | 1 | 0 | |a Toward a genome-based treatment landscape for renal cell carcinoma |
264 | 1 | |c 2019 | |
300 | |a 12 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a • Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection. | ||
650 | 7 | |a RCC |2 Elsevier | |
650 | 7 | |a Genomic landscape |2 Elsevier | |
650 | 7 | |a Oncocytoma |2 Elsevier | |
650 | 7 | |a Genomic mutations |2 Elsevier | |
650 | 7 | |a Papillary RCC |2 Elsevier | |
650 | 7 | |a Chromophobe RCC |2 Elsevier | |
650 | 7 | |a Clear cell RCC |2 Elsevier | |
700 | 1 | |a Di Nunno, Vincenzo |4 oth | |
700 | 1 | |a Santoni, Matteo |4 oth | |
700 | 1 | |a Gatto, Lidia |4 oth | |
700 | 1 | |a Caserta, Claudia |4 oth | |
700 | 1 | |a Morelli, Franco |4 oth | |
700 | 1 | |a Zafarana, Elena |4 oth | |
700 | 1 | |a Carrozza, Francesco |4 oth | |
700 | 1 | |a Mosca, Alessandra |4 oth | |
700 | 1 | |a Mollica, Veronica |4 oth | |
700 | 1 | |a Iacovelli, Roberto |4 oth | |
700 | 1 | |a Sabbatini, Roberto |4 oth | |
700 | 1 | |a Porta, Camillo |4 oth | |
700 | 1 | |a Bracarda, Sergio |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Dettori, D. ELSEVIER |t miR-214 in stroma cells and tumor progression |d 2016 |g Amsterdam [u.a.] |w (DE-627)ELV019637179 |
773 | 1 | 8 | |g volume:142 |g year:2019 |g pages:141-152 |g extent:12 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.critrevonc.2019.07.020 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2016 | ||
912 | |a GBV_ILN_2048 | ||
936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
951 | |a AR | ||
952 | |d 142 |j 2019 |h 141-152 |g 12 |
author_variant |
f m fm |
---|---|
matchkey_str |
massarifrancescodinunnovincenzosantonima:2019----:oadgnmbsdramnlnsaeorn |
hierarchy_sort_str |
2019 |
bklnumber |
44.52 |
publishDate |
2019 |
allfields |
10.1016/j.critrevonc.2019.07.020 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000992.pica (DE-627)ELV047908513 (ELSEVIER)S1040-8428(19)30164-7 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Massari, Francesco verfasserin aut Toward a genome-based treatment landscape for renal cell carcinoma 2019 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection. RCC Elsevier Genomic landscape Elsevier Oncocytoma Elsevier Genomic mutations Elsevier Papillary RCC Elsevier Chromophobe RCC Elsevier Clear cell RCC Elsevier Di Nunno, Vincenzo oth Santoni, Matteo oth Gatto, Lidia oth Caserta, Claudia oth Morelli, Franco oth Zafarana, Elena oth Carrozza, Francesco oth Mosca, Alessandra oth Mollica, Veronica oth Iacovelli, Roberto oth Sabbatini, Roberto oth Porta, Camillo oth Bracarda, Sergio oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:142 year:2019 pages:141-152 extent:12 https://doi.org/10.1016/j.critrevonc.2019.07.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 142 2019 141-152 12 |
spelling |
10.1016/j.critrevonc.2019.07.020 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000992.pica (DE-627)ELV047908513 (ELSEVIER)S1040-8428(19)30164-7 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Massari, Francesco verfasserin aut Toward a genome-based treatment landscape for renal cell carcinoma 2019 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection. RCC Elsevier Genomic landscape Elsevier Oncocytoma Elsevier Genomic mutations Elsevier Papillary RCC Elsevier Chromophobe RCC Elsevier Clear cell RCC Elsevier Di Nunno, Vincenzo oth Santoni, Matteo oth Gatto, Lidia oth Caserta, Claudia oth Morelli, Franco oth Zafarana, Elena oth Carrozza, Francesco oth Mosca, Alessandra oth Mollica, Veronica oth Iacovelli, Roberto oth Sabbatini, Roberto oth Porta, Camillo oth Bracarda, Sergio oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:142 year:2019 pages:141-152 extent:12 https://doi.org/10.1016/j.critrevonc.2019.07.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 142 2019 141-152 12 |
allfields_unstemmed |
10.1016/j.critrevonc.2019.07.020 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000992.pica (DE-627)ELV047908513 (ELSEVIER)S1040-8428(19)30164-7 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Massari, Francesco verfasserin aut Toward a genome-based treatment landscape for renal cell carcinoma 2019 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection. RCC Elsevier Genomic landscape Elsevier Oncocytoma Elsevier Genomic mutations Elsevier Papillary RCC Elsevier Chromophobe RCC Elsevier Clear cell RCC Elsevier Di Nunno, Vincenzo oth Santoni, Matteo oth Gatto, Lidia oth Caserta, Claudia oth Morelli, Franco oth Zafarana, Elena oth Carrozza, Francesco oth Mosca, Alessandra oth Mollica, Veronica oth Iacovelli, Roberto oth Sabbatini, Roberto oth Porta, Camillo oth Bracarda, Sergio oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:142 year:2019 pages:141-152 extent:12 https://doi.org/10.1016/j.critrevonc.2019.07.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 142 2019 141-152 12 |
allfieldsGer |
10.1016/j.critrevonc.2019.07.020 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000992.pica (DE-627)ELV047908513 (ELSEVIER)S1040-8428(19)30164-7 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Massari, Francesco verfasserin aut Toward a genome-based treatment landscape for renal cell carcinoma 2019 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection. RCC Elsevier Genomic landscape Elsevier Oncocytoma Elsevier Genomic mutations Elsevier Papillary RCC Elsevier Chromophobe RCC Elsevier Clear cell RCC Elsevier Di Nunno, Vincenzo oth Santoni, Matteo oth Gatto, Lidia oth Caserta, Claudia oth Morelli, Franco oth Zafarana, Elena oth Carrozza, Francesco oth Mosca, Alessandra oth Mollica, Veronica oth Iacovelli, Roberto oth Sabbatini, Roberto oth Porta, Camillo oth Bracarda, Sergio oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:142 year:2019 pages:141-152 extent:12 https://doi.org/10.1016/j.critrevonc.2019.07.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 142 2019 141-152 12 |
allfieldsSound |
10.1016/j.critrevonc.2019.07.020 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000992.pica (DE-627)ELV047908513 (ELSEVIER)S1040-8428(19)30164-7 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Massari, Francesco verfasserin aut Toward a genome-based treatment landscape for renal cell carcinoma 2019 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection. RCC Elsevier Genomic landscape Elsevier Oncocytoma Elsevier Genomic mutations Elsevier Papillary RCC Elsevier Chromophobe RCC Elsevier Clear cell RCC Elsevier Di Nunno, Vincenzo oth Santoni, Matteo oth Gatto, Lidia oth Caserta, Claudia oth Morelli, Franco oth Zafarana, Elena oth Carrozza, Francesco oth Mosca, Alessandra oth Mollica, Veronica oth Iacovelli, Roberto oth Sabbatini, Roberto oth Porta, Camillo oth Bracarda, Sergio oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:142 year:2019 pages:141-152 extent:12 https://doi.org/10.1016/j.critrevonc.2019.07.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 142 2019 141-152 12 |
language |
English |
source |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:142 year:2019 pages:141-152 extent:12 |
sourceStr |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:142 year:2019 pages:141-152 extent:12 |
format_phy_str_mv |
Article |
bklname |
Therapie |
institution |
findex.gbv.de |
topic_facet |
RCC Genomic landscape Oncocytoma Genomic mutations Papillary RCC Chromophobe RCC Clear cell RCC |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
miR-214 in stroma cells and tumor progression |
authorswithroles_txt_mv |
Massari, Francesco @@aut@@ Di Nunno, Vincenzo @@oth@@ Santoni, Matteo @@oth@@ Gatto, Lidia @@oth@@ Caserta, Claudia @@oth@@ Morelli, Franco @@oth@@ Zafarana, Elena @@oth@@ Carrozza, Francesco @@oth@@ Mosca, Alessandra @@oth@@ Mollica, Veronica @@oth@@ Iacovelli, Roberto @@oth@@ Sabbatini, Roberto @@oth@@ Porta, Camillo @@oth@@ Bracarda, Sergio @@oth@@ |
publishDateDaySort_date |
2019-01-01T00:00:00Z |
hierarchy_top_id |
ELV019637179 |
dewey-sort |
3610 |
id |
ELV047908513 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047908513</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624141859.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191023s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2019.07.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000992.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047908513</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(19)30164-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Massari, Francesco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Toward a genome-based treatment landscape for renal cell carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Genomic landscape</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oncocytoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Genomic mutations</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Papillary RCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chromophobe RCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clear cell RCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di Nunno, Vincenzo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoni, Matteo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gatto, Lidia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Caserta, Claudia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morelli, Franco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zafarana, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carrozza, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mosca, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mollica, Veronica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Iacovelli, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sabbatini, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Porta, Camillo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bracarda, Sergio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:142</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:141-152</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2019.07.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">142</subfield><subfield code="j">2019</subfield><subfield code="h">141-152</subfield><subfield code="g">12</subfield></datafield></record></collection>
|
author |
Massari, Francesco |
spellingShingle |
Massari, Francesco ddc 610 bkl 44.52 Elsevier RCC Elsevier Genomic landscape Elsevier Oncocytoma Elsevier Genomic mutations Elsevier Papillary RCC Elsevier Chromophobe RCC Elsevier Clear cell RCC Toward a genome-based treatment landscape for renal cell carcinoma |
authorStr |
Massari, Francesco |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019637179 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 VZ 44.52 bkl Toward a genome-based treatment landscape for renal cell carcinoma RCC Elsevier Genomic landscape Elsevier Oncocytoma Elsevier Genomic mutations Elsevier Papillary RCC Elsevier Chromophobe RCC Elsevier Clear cell RCC Elsevier |
topic |
ddc 610 bkl 44.52 Elsevier RCC Elsevier Genomic landscape Elsevier Oncocytoma Elsevier Genomic mutations Elsevier Papillary RCC Elsevier Chromophobe RCC Elsevier Clear cell RCC |
topic_unstemmed |
ddc 610 bkl 44.52 Elsevier RCC Elsevier Genomic landscape Elsevier Oncocytoma Elsevier Genomic mutations Elsevier Papillary RCC Elsevier Chromophobe RCC Elsevier Clear cell RCC |
topic_browse |
ddc 610 bkl 44.52 Elsevier RCC Elsevier Genomic landscape Elsevier Oncocytoma Elsevier Genomic mutations Elsevier Papillary RCC Elsevier Chromophobe RCC Elsevier Clear cell RCC |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
n v d nv nvd m s ms l g lg c c cc f m fm e z ez f c fc a m am v m vm r i ri r s rs c p cp s b sb |
hierarchy_parent_title |
miR-214 in stroma cells and tumor progression |
hierarchy_parent_id |
ELV019637179 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
miR-214 in stroma cells and tumor progression |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV019637179 |
title |
Toward a genome-based treatment landscape for renal cell carcinoma |
ctrlnum |
(DE-627)ELV047908513 (ELSEVIER)S1040-8428(19)30164-7 |
title_full |
Toward a genome-based treatment landscape for renal cell carcinoma |
author_sort |
Massari, Francesco |
journal |
miR-214 in stroma cells and tumor progression |
journalStr |
miR-214 in stroma cells and tumor progression |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2019 |
contenttype_str_mv |
zzz |
container_start_page |
141 |
author_browse |
Massari, Francesco |
container_volume |
142 |
physical |
12 |
class |
610 VZ 44.52 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Massari, Francesco |
doi_str_mv |
10.1016/j.critrevonc.2019.07.020 |
dewey-full |
610 |
title_sort |
toward a genome-based treatment landscape for renal cell carcinoma |
title_auth |
Toward a genome-based treatment landscape for renal cell carcinoma |
abstract |
• Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection. |
abstractGer |
• Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection. |
abstract_unstemmed |
• Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 |
title_short |
Toward a genome-based treatment landscape for renal cell carcinoma |
url |
https://doi.org/10.1016/j.critrevonc.2019.07.020 |
remote_bool |
true |
author2 |
Di Nunno, Vincenzo Santoni, Matteo Gatto, Lidia Caserta, Claudia Morelli, Franco Zafarana, Elena Carrozza, Francesco Mosca, Alessandra Mollica, Veronica Iacovelli, Roberto Sabbatini, Roberto Porta, Camillo Bracarda, Sergio |
author2Str |
Di Nunno, Vincenzo Santoni, Matteo Gatto, Lidia Caserta, Claudia Morelli, Franco Zafarana, Elena Carrozza, Francesco Mosca, Alessandra Mollica, Veronica Iacovelli, Roberto Sabbatini, Roberto Porta, Camillo Bracarda, Sergio |
ppnlink |
ELV019637179 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth |
doi_str |
10.1016/j.critrevonc.2019.07.020 |
up_date |
2024-07-06T17:26:51.050Z |
_version_ |
1803851463184613376 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047908513</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624141859.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191023s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2019.07.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000992.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047908513</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(19)30164-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Massari, Francesco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Toward a genome-based treatment landscape for renal cell carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Renal cell carcinoma is characterized by different genomic alterations and and variable mutations acquired in later phase of disease. • Genomic alteration profile reflects tumor escapes from different external pressure. • Metabolic, genomic and immune treatment related external pressure might influence mutations development in RCC. • Better knowledge of RCC genomic landscape may lead to development of new tailored treatment for an accurate patients’ selection.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Genomic landscape</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oncocytoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Genomic mutations</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Papillary RCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chromophobe RCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clear cell RCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di Nunno, Vincenzo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoni, Matteo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gatto, Lidia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Caserta, Claudia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morelli, Franco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zafarana, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carrozza, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mosca, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mollica, Veronica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Iacovelli, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sabbatini, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Porta, Camillo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bracarda, Sergio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:142</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:141-152</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2019.07.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">142</subfield><subfield code="j">2019</subfield><subfield code="h">141-152</subfield><subfield code="g">12</subfield></datafield></record></collection>
|
score |
7.400732 |